文献速递浆细胞疾病

多发性骨髓瘤临床试验中不同种族和民族人群的入组标准与入组情况

Eligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trials.
PubMed 文献 · Blood · 2023-01-01

该研究回顾性汇总分析了2006至2019年提交美国食品药品监督管理局支持多发性骨髓瘤疗法获批的多中心全球临床试验,按种族和民族分析不合格率及原因。黑人(24%)和其他种族(23%)患者的不合格率高于白人(17%),亚裔最低(12%)。黑人患者因血液学实验室标准(19%)和治疗相关标准(17%)不合格最常见;白人和亚裔分别因疾病相关标准(28%和29%)不合格最常见。

要点

  • 黑人(24%)和其他种族(23%)患者的不合格率高于白人(17%)。
  • 亚裔不合格率最低(12%)。
  • 黑人患者不合格最常见原因为血液学实验室标准(19%)和治疗相关标准(17%)。

核心结论

  • 分析表明,特定的入组标准可能促成多发性骨髓瘤临床试验中不同种族和民族亚组之间的入组差异。
  • 然而,代表性不足的种族和民族亚组中筛查患者数量少,限制了确定性结论。

研究设计与样本

  • 回顾性汇总分析,纳入2006至2019年提交美国食品药品监督管理局支持多发性骨髓瘤疗法获批的多中心全球临床试验。
  • 按美国管理和预算办公室标准编码种族和民族,被标记为筛查失败的患者认定为不合格。
  • 不合格率计算为各相应种族和民族亚组中不合格患者占筛查人群的百分比。

主要发现

  • 黑人患者不合格率为24%,其他种族为23%,均高于白人患者的17%。
  • 亚裔不合格率为12%,在所有种族亚组中最低。
  • 黑人患者中最常见的不合格原因为未满足血液学实验室标准(19%)和治疗相关标准(17%),且这些原因在黑人患者中比其他种族更常见。
  • 白人和亚裔参与者中最常见的不合格原因为未满足疾病相关标准,分别为28%和29%。

局限性

  • 代表性不足的种族和民族亚组中筛查患者数量少,限制了确定性结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The narrow eligibility criteria may contribute to the underrepresentation of racial and ethnic subgroups in cancer clinical trials. We conducted a retrospective pooled analysis of multicenter global clinical trials submitted to the US Food and Drug Administration between 2006 and 2019 to support the approval of the use of multiple myeloma (MM) therapies that analyze the rates and reasons for trial ineligibility based on race and ethnicity in MM clinical trials. Race and ethnicity were coded per Office of Management and Budget standards. Patients flagged as having screen failures were identified as ineligible. Ineligibility rates were calculated as the percentage of patients who were ineligible compared with the screened population within the respective racial and ethnic subgroups. Trial eligibility criteria were grouped into specific categories to analyze the reasons for trial ineligibility. Black patients (24%) and other (23%) race subgroups had higher ineligibility rates than White patients (17%). The Asian race had the lowest ineligibility rate (12%) among all racial subgroups. Failure to meet the hematologic laboratory criteria (19%) and treatment-related criteria (17%) were the most common reasons for ineligibility among Black patients and were more common in Black patients than in other races. Failure to meet disease-related criteria was the most common reason for ineligibility among White (28%) and Asian (29%) participants. Our analysis indicates that specific eligibility criteria may contribute to enrollment disparities for racial and ethnic subgroups in MM clinical trials. However, the small number of screened patients in the underrepresented racial and ethnic subgroups limits definitive conclusions.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kanapuru B, Fernandes LL, Baines A, et al. Eligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trials. Blood. 2023. PMID: 37140031. doi:10.1182/blood.2022018657

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。